11-20 of 585
Post: Groups Seek More FDA Flexibility in Early Cell Therapy Development
A new white paper from the Friends of Cancer Research (FOCR) and the Parker Institute for Cancer Immunotherapy calls on the...
Post: Anxious Lawyers Hindering Cutting-Edge Drugs, Scientists Say
Commercial-grade manufacturing requirements from institutions holding back cell therapies Draft guidance from FDA in the works A risk-averse culture at universities...
Post: Melanoma Investigators Strive to Overcome PD-1 Inhibitor Resistance
Approximately one-third to one-half of patients with advanced melanoma respond to PD-1 inhibitor therapy, which is superior to response rates observed...
Post: Friends, Parker Institute call for more flexibility in early T cell therapy development
Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy recommend more flexible IND and manufacturing requirements and the use...
Post: NEC Becomes the First Japanese Company to Join the TESLA Consortium’s Fight Against Cancer
NEC Corporation has become the first Japanese company to join the Tumor neoantigEn SeLection Alliance (TESLA) founded and managed by the...
